<DOC>
	<DOCNO>NCT00257790</DOCNO>
	<brief_summary>Evaluate tobramycin give day least efficacious traditional tobramycin give three time day , give penicillin G , til patient febrile neutropenia .</brief_summary>
	<brief_title>The Tobramycin Study</brief_title>
	<detailed_description>Prospective randomize Norwegian multicenter clinical trial ( 11 hospital ) compare tobramycin give day ( new regimen ) vs. three time day ( current regimen ) , penicillin G , cancer patient febrile neutropenia . Tobramycin half life postantibiotic effect best 12 hour . It question tobramycin day safe patient low level granulocyte give drug like penicillin G cover Gram-negative rod . Treatment febrile neutropenia penicillin G aminoglycoside standard care Norway , probably regimen promote antimicrobial resistance less broad spectrum beta-lactam . Cancer patient 16-70 febrile neutropenia sign informed consent could randomize . Exclusion criterion allergy study medication , increase creatinine/renal failure , massive ascites , multiple myeloma , treatment cis-platinum , recent therapy aminoglycoside ( 4 week ) antibiotic ( 4 day ) , hemodynamically unstable patient , pregnant nursing patient . Patients stratify three group : Leukemia patient receive intensive chemotherapy , lymphoma patient receive high dose chemotherapy autologous stem-cell support cancer patient . Patients randomize either tobramycin three time day . Once patient randomize first antibiotic dose give , antibiotic therapy patient 's doctor 's discretion ( blind ) . Everybody receive tobramycin 6 mg/kg/day penicillin 5 mill . IE four time day . The patient follow antibiotic therapy terminate . Clinical condition laboratory test result time randomization ( new fever ) register . Response therapy , reason modification therapy , mortality , duration neutropenia , maximum creatinine level , tobramycin serum concentration , microbiological finding total antibiotic consumption register . After external monitoring data result currently make available publication 2006 . This trial conduct independently pharmaceutical industry . Grants receive The Norwegian Radium Hospital research fund , The Regional Health Authorities The Norwegian Society Infectious Diseases .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Febrile neutropenia Cancer Adult ( 1670 ) Signed informed consent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Fever</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Tobramycin</keyword>
	<keyword>Aminoglycoside</keyword>
	<keyword>Penicillin</keyword>
</DOC>